Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/17/2014 11/18/2014 11/19/2014 11/20/2014 11/21/2014 Date
88.98(c) 89.95(c) 89.57(c) 89.74(c) 92.6219 Last
670 312 647 719 545 939 359 480 280 329 Volume
-1.26% +1.09% -0.42% +0.19% +3.21% Change
More quotes
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference.It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
Surperformance© rating of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 36,5 M
EBIT 2014 -369 M
Net income 2014 -356 M
Finance 2014 748 M
Yield 2014 -
Sales 2015 51,5 M
EBIT 2015 -206 M
Net income 2015 -204 M
Finance 2015 676 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 169x
EV / Sales 2015 121x
Capitalization 6 904 M
More Financials
Latest news on ALNYLAM PHARMACEUTICALS, I
2d ago ALNYLAM PHARMACEUTICALS : Expands Hepatic Infectious Disease Pipeline; Adds ALN-..
2d ago ALNYLAM PHARMACEUTICALS : Issues Initial Phase 2 Data with Revusiran (ALN-TTRsc)
4d ago ALNYLAM PHARMACEUTICALS : Presents New Pre-Clinical Data on RNAi Therapeutic Pro..
11/14 ALNYLAM PHARMACEUTICALS : Announces Positive Initial Phase 2 Data with Revusiran..
11/11 ALNYLAM PHARMACEUTICALS : Expands Hepatic Infectious Disease Pipeline; Adds ALN-..
11/11 ALNYLAM PHARMACEUTICALS : Assigned Patent
11/09 ALNYLAM PHARMACEUTICALS : Selects Dr. Pushkal Garg as SVP, Clinical Development
11/06 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at the Credit Suisse 2014 Heal..
11/05 ALNYLAM PHARMACEUTICALS : Appoints Pushkal Garg, M.D., Senior Vice President, Cl..
11/05 ALNYLAM PHARMACEUTICALS : beats Street 3Q forecasts
11/05 ALNYLAM PHARMACEUTICALS : and The Medicines Company Announce Filing of a Clinica..
11/05 ALNYLAM PHARMACEUTICALS : Results of Operations and Financial Condition, Financi..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF